Buscar
Silence Therapeutics PLC
SLNAñadir a la lista de seguimiento
10.390USD
-0.110-1.05%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
490.76MCap. mercado
PérdidaP/E TTM
Más Datos de Silence Therapeutics PLC Compañía
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Información de Silence Therapeutics PLC
Símbolo de cotizaciónSLN
Nombre de la empresaSilence Therapeutics PLC
Fecha de salida a bolsaJan 05, 2010
Director ejecutivoTooman (Craig A)
Número de empleados116
Tipo de seguridadDepository Receipt
Fin del año fiscalJan 05
Dirección72 Hammersmith Road
CiudadLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW14 8TH
Teléfono442034576900
Sitio Webhttps://www.silence-therapeutics.com/
Símbolo de cotizaciónSLN
Fecha de salida a bolsaJan 05, 2010
Director ejecutivoTooman (Craig A)
Ejecutivos de Silence Therapeutics PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Silence Therapeutics PLC?
Los cinco principales accionistas de Silence Therapeutics PLC son: Mr. David Jakob (Dave) Lemus, CPA
¿Cuántas instituciones poseen acciones de Silence Therapeutics PLC (SLN)?
A fecha de 2026Q1, 147 instituciones poseen acciones de Silence Therapeutics PLC, con un valor de mercado combinado de aproximadamente 19.17M, lo que representa el 40.59% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -12508865.00.